YD Bio Limited H1 2026 Earnings: Revenue Soars 315% to $0.85M as Warrant Revaluation Drives $6.70M Profit

Quick Verdict

This article discusses the YD Bio Limited H1 2026 Earnings and their market impact. YD Bio Limited reported H1 2026 EPS of $0.09 and revenue of $0.85 million, up 315% year over year. Net income reached $6.70 million, but it was primarily driven by a non-cash warrant-liability fair-value gain. Shares fell sharply during the regular session, implying a cautious market interpretation.

About YD Bio Limited

YD Bio Limited (Nasdaq: YDES) is a biotechnology company focused on DNA methylation-based cancer detection, regulated molecular diagnostics, clinical services, precision medicine, ophthalmologic commercialization, and life-science distribution. Its business model spans blood-based oncology testing through a laboratory-developed-test strategy, telehealth access, clinical-trial supply-chain services, regenerative ophthalmology, and licensed limbal stem-cell/exosome technologies.

The company is incorporated in the Cayman Islands and was formed in March 2024; its principal executive office is in Nangang District, Taipei, Taiwan. Its shares began Nasdaq trading in August 2025. The company had 70.84 million ordinary shares outstanding as of June 30, 2026. Based on the August 31 market close/range cited by market-data providers, YDES had an approximate market capitalization of $276 million–$340 million. YD Bio did not report a dividend yield, and common stock-screening services showed P/E as not meaningful, reflecting its recent losses and unusually large non-cash accounting gain in H1 2026.

Top Financial Highlights

1. Net revenue increased 315% year over year to $846,501, from $204,007 in H1 2025.
2. Gross profit rose 290% to $268,230, compared with $68,795 a year earlier.
3. Gross margin was approximately 31.7%, versus approximately 33.7% in H1 2025, indicating a roughly 200-basis-point contraction as the sales mix included a large lower-margin order.
4. Cost of revenue climbed 328% to $578,271, faster than revenue growth.
5. Reported net income was $6.70 million, reversing a $1.92 million net loss in H1 2025.
6. Basic and diluted EPS was $0.09, compared with a loss per share of $0.03 in the prior-year period.
7. The reported profit was substantially attributable to a $9.85 million non-cash gain from the change in fair value of warrant liabilities.
8. Operating loss widened 66% to $3.23 million, from $1.95 million, underscoring that core operations remained loss-making.
9. Excluding the warrant-liability revaluation, management said the operational net loss increased 64% to about $3.1 million.
10. Operating cash flow was negative: net cash used in operating activities totaled $2.82 million, compared with $2.16 million used in H1 2025.
11. Cash and cash equivalents stood at $2.66 million at June 30, 2026, down from $6.01 million at December 31, 2025.
12. Current assets were $5.59 million, while current liabilities were $1.07 million, representing a reported current ratio of about 5.2x.
13. The largest product, Fetroja for Injection, generated $327,060, or approximately 39% of H1 revenue.
14. Keytruda Injection contributed $55,426, while Universal High-Speed Refrigerated Centrifuge sales contributed $45,504.
15. The five largest products generated $481,745, equal to roughly 57% of H1 revenue, indicating material product concentration.

Beat or Miss?

YD Bio’s release does not provide analyst revenue, EPS, or earnings estimates. As a result, a formal consensus “beat” or “miss” cannot be determined. The company’s headline revenue growth and net-income reversal were strong, but the profit quality was mixed because the reported bottom line was dominated by a non-cash warrant-liability valuation gain rather than an operating profit.

The central analytical distinction is between reported accounting income and recurring operating performance: H1 profit did not translate into positive operating cash flow, and the operating loss widened as YD Bio increased R&D, staffing, consulting, and marketing expenditures.

What Leadership Is Saying

“The first half of 2026 marks a historic turning point for YD Bio, highlighted by our transition to bottom-line profitability and a remarkable 315% surge in top-line revenue.” — Dr. Ethan Shen, Chairman and CEO.

“While our net income of $6.7 million was propelled by non-cash adjustments in the fair value of our warrant liabilities, our structural baseline has never been stronger.” — Dr. Ethan Shen, Chairman and CEO.

Historical Performance

Because this release covers the six months ended June 30, the appropriate comparison is H1 2026 versus H1 2025 rather than a single quarter.

The major swing in net income should not be read as a proportionate improvement in operating economics. Revenue and gross profit expanded meaningfully, but expenses increased 73%, operating losses deepened, and cash used in operations increased. The reported income improvement reflects the $9.85 million favorable revaluation of warrant liabilities.

How the Market Reacted?

YDES shares declined sharply on August 31, the date of the results release. Benzinga reported that the shares were down 17.09% to $3.98 during the regular session, while another market-data source showed a closing price of $3.71, down 22.71% for the day. The variation reflects different intraday versus end-of-day timestamps, but both point to a strongly negative immediate reaction.

The market response appears consistent with investor focus on the quality and sustainability of earnings: reported net income was positive, but core operations recorded a $3.23 million loss, operating cash outflow totaled $2.82 million, cash fell to $2.66 million, and management explicitly highlighted the need to manage its operational runway. The headline revenue growth was substantial, but the concentration of revenue in a few products and the non-cash nature of the warrant-related gain likely tempered sentiment.